Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III randomized double-blind trial of SHR-1210 in cancer patients with sepsis
ChiCTR1800020099Phase 3Recruiting
- Sponsor
- Harbin Medical University Cancer Hospital
- Start
- Dec 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in sepsis and Nonhematologic neoplasms comparing SHR-1210 group with Placebo control group (2 arms). Primary endpoint: 28-day mortality. Started Dec 2018; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
sepsisNonhematologic neoplasms
Beyond the preview
Go deeper on ChiCTR1800020099.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800020099.